NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
Clinical trial NCT05569811 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05569811
- Sponsor
- SOLTI Breast Cancer Research Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-25
- Primary completion
- 2025-03-31
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.